
News
AOP Health presents final results from its CONTINUATION-PV study -up to 7.5 years treatment with BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera patients - at EHA 2022 Annual Meeting
13. 6. 2022AOP Health Submits New Drug Application for Landiolol, Seeking Approval in the United States
2. 6. 2022AOP Health opens its Italian base in Pisa
20. 5. 2022

AOP Health headquarters team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.

Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Health headquarters using the link below.

In the field of rare diseases the AOP Health team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.